Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.

(2021) Saad Zafar Usmani et al.   JOURNAL OF CLINICAL ONCOLOGY

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

(2020) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

(2020) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Engineering and Design of Chimeric Antigen Receptors

(2019) Sonia Guedan et al.   Molecular Therapy-Methods & Clinical Development

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

Estimating hazard ratios from published Kaplan‐Meier survival curves: A methods validation study

(2019) Ronak Saluja et al.   Research Synthesis Methods

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials

(2018) Naveen Mangal et al.   HEMATOLOGICAL ONCOLOGY

Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy

(2018) Noelle Frey et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal

(2017) David M. Phillippo et al.   MEDICAL DECISION MAKING

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

(2017) Nikhil C. Munshi et al.   JAMA Oncology

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research

(2012) James E. Signorovitch et al.   VALUE IN HEALTH

Comparative Effectiveness Without Head-to-Head Trials

(2010) James E. Signorovitch et al.   PHARMACOECONOMICS